company background image
VIR logo

Vir Biotechnology NasdaqGS:VIR Stock Report

Last Price

US$10.13

Market Cap

US$1.4b

7D

0.4%

1Y

-56.0%

Updated

28 Mar, 2024

Data

Company Financials +

Vir Biotechnology, Inc.

NasdaqGS:VIR Stock Report

Market Cap: US$1.4b

VIR Stock Overview

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.

VIR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Vir Biotechnology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vir Biotechnology
Historical stock prices
Current Share PriceUS$10.13
52 Week HighUS$27.48
52 Week LowUS$7.72
Beta0.42
1 Month Change-11.37%
3 Month Change0.70%
1 Year Change-55.96%
3 Year Change-79.56%
5 Year Changen/a
Change since IPO-27.75%

Recent News & Updates

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Feb 28

Recent updates

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Feb 28

Sticking With Vir Biotechnology

Jan 17

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Aug 07
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Jul 24
Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Feb 28
Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 07
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate

Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off

Oct 12

Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B

Oct 04

Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus

Sep 22

Vir Biotechnology falls 15% on Q2 revenue miss impacted by ~$400M for potential write-offs

Aug 09

Vir: Biotechnology's Best Near-Term Capital Gain Prospect

Jul 27

Vir Biotechnology announces transition of chief scientific officer

Jul 14

Shareholder Returns

VIRUS BiotechsUS Market
7D0.4%0.9%0.4%
1Y-56.0%10.3%28.8%

Return vs Industry: VIR underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: VIR underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is VIR's price volatile compared to industry and market?
VIR volatility
VIR Average Weekly Movement7.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: VIR has not had significant price volatility in the past 3 months.

Volatility Over Time: VIR's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016587Marianne De Backerhttps://www.vir.bio

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.

Vir Biotechnology, Inc. Fundamentals Summary

How do Vir Biotechnology's earnings and revenue compare to its market cap?
VIR fundamental statistics
Market capUS$1.36b
Earnings (TTM)-US$615.06m
Revenue (TTM)US$86.18m

15.9x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIR income statement (TTM)
RevenueUS$86.18m
Cost of RevenueUS$509.41m
Gross Profit-US$423.23m
Other ExpensesUS$191.83m
Earnings-US$615.06m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.55
Gross Margin-491.10%
Net Profit Margin-713.69%
Debt/Equity Ratio0%

How did VIR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.